Physician profile
Peter Mcallister
NPI 1033176896
$2,301,288.71
in general payments reported to CMS, 2019-2025
98 companies · $406K in 2025
The $406K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $247K · 2020: $266K · 2021: $328K · 2022: $422K · 2023: $330K · 2024: $302K · 2025: $406K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $346K · Consulting Fee: $247K · Honoraria: $220K · Travel and Lodging: $185K · Food and Beverage: $40K · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $346,024.51 |
| Consulting Fee | $247,267.25 |
| Honoraria | $219,872.38 |
| Travel and Lodging | $185,405.73 |
| Food and Beverage | $39,750.25 |
| Education | $190.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $467,436.46 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Abbvie INC. | $460,974.14 | 2021-2025 | |
| H. Lundbeck A S | $297,858.17 | 2021-2025 | Vyepti, Eptinezumab |
| Lundbeck LLC | $163,805.85 | 2019-2025 | Vyepti |
| Allergan, INC. | $156,064.31 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $141,829.13 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Amgen INC. | $115,862.29 | 2019-2025 | Uplizna, Aimovig |
| Impel Pharmaceuticals INC. | $115,363.12 | 2022-2023 | Trudhesa |
| Upsher-Smith Laboratories LLC | $50,259.52 | 2019-2023 | |
| Merz Pharmaceuticals, LLC | $45,855.11 | 2021-2025 | Xeomin, Inbrija |
| Ani Pharmaceuticals, INC. | $41,269.51 | 2022-2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $39,903.70 | 2022-2025 | Symbravo, Auvelity |
| Pfizer INC. | $31,925.28 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $25,675.55 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17,083.84 | 2020-2021 |
Show all 94 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $14,534.37 | 2020-2022 | |
| Dompe US, INC. | $14,348.31 | 2025 | Oxervate |
| Eisai INC. | $14,074.19 | 2019-2025 | |
| Novartis Pharma Ag | $13,820.81 | 2019 | |
| Eli Lilly and Company | $11,031.81 | 2019-2025 | Kisunla |
| Novartis Pharmaceuticals Corporation | $6,139.48 | 2019-2025 | |
| Promius Pharma LLC | $5,363.69 | 2019 | |
| Pfizer International LLC | $4,800.00 | 2025 | |
| Evoke Pharma, INC. | $4,307.69 | 2024 | |
| Bausch Health US, LLC | $3,654.71 | 2019-2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $2,514.98 | 2021-2024 | Belbuca |
| Mdd US Operations, LLC | $2,205.92 | 2019-2025 | Gocovri, Gocovri |
| Genentech USA, INC. | $2,036.20 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Tonix Medicines, INC. | $2,031.64 | 2023-2025 | Zembrace Symtouch |
| Amneal Pharmaceuticals LLC | $1,829.03 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Scilex Pharmaceuticals INC. | $1,784.50 | 2022-2025 | Elyxyb, Ztlido |
| Emd Serono, INC. | $1,633.92 | 2019-2025 | Mavenclad |
| Csl Behring | $1,624.71 | 2019-2025 | Hizentra |
| Avanir Pharmaceuticals, INC. | $1,570.39 | 2019-2022 | |
| Ucb, INC. | $1,496.69 | 2019-2025 | Rystiggo, Fintepla, Nayzilam |
| Acorda Therapeutics, INC | $1,422.44 | 2019-2024 | Inbrija, Ampyra |
| Neurocrine Biosciences, INC. | $1,339.10 | 2019-2025 | Ingrezza, Ongentys |
| Neurelis, INC. | $1,239.91 | 2022-2024 | Valtoco |
| Argenx US, INC. | $1,206.11 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Harmony Biosciences LLC | $1,040.74 | 2020-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $980.63 | 2019-2025 | Hyqvia, Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $921.81 | 2022-2025 | Caplyta |
| Sk Life Science, INC. | $825.59 | 2020-2024 | |
| Biogen, INC. | $703.56 | 2019-2025 | Vumerity, Tysabri |
| Celgene Corporation | $696.27 | 2021-2025 | Zeposia |
| Genzyme Corporation | $666.81 | 2019-2023 | |
| Ipsen Biopharmaceuticals, INC | $658.53 | 2020-2025 | Dysport |
| Jazz Pharmaceuticals INC. | $446.05 | 2019-2025 | |
| Grifols USA, LLC | $424.39 | 2019-2025 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $356.61 | 2020-2025 | Acthar |
| Sunovion Pharmaceuticals INC. | $342.29 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $301.98 | 2019-2025 | Qelbree |
| Xeris Pharmaceuticals, INC. | $301.17 | 2021-2025 | Keveyis, Gvoke Hypopen |
| Janssen Pharmaceuticals, INC | $298.49 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $288.50 | 2019-2025 | Contrave, Onzetra Xsail |
| Idorsia Pharmaceuticals US INC | $275.39 | 2022-2023 | Quviviq |
| Assertio Therapeutics, INC. | $273.30 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $250.02 | 2020-2023 | Belsomra |
| Kyowa Kirin, INC. | $244.70 | 2019-2024 | Nourianz |
| Alnylam Pharmaceuticals INC. | $241.17 | 2020-2025 | Onpattro |
| Adamas Pharmaceuticals, INC. | $240.30 | 2020-2021 | |
| Strongbridge US INC. | $233.92 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $224.16 | 2019-2020 | |
| Horizon Therapeutics Plc | $220.19 | 2021-2023 | Uplizna |
| Abbott Laboratories | $211.52 | 2021-2025 | Infinity |
| Ironshore Pharmaceuticals INC. | $200.30 | 2019-2023 | Jornay Pm |
| Boston Scientific Corporation | $182.51 | 2024-2025 | Watchman Flx |
| Revance Therapeutics, INC. | $179.05 | 2024 | Daxxify |
| Adlon Therapeutics L.P. | $173.59 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $164.18 | 2020-2022 | |
| Alexion Pharmaceuticals, INC. | $163.46 | 2019-2021 | |
| Akcea Therapeutics, INC. | $155.55 | 2019-2021 | |
| Corium, LLC | $140.57 | 2022-2025 | Azstarys |
| Merz North America, INC. | $132.07 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $130.02 | 2020-2022 | |
| Zyla Life Sciences, INC. | $112.64 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $85.44 | 2021-2025 | Rexulti |
| Impel Pharmaceuticals LLC | $65.36 | 2024-2025 | Trudhesa |
| Avion Pharmaceuticals | $56.27 | 2022 | |
| Sumitomo Pharma America, INC. | $53.30 | 2023 | Aptiom |
| Genentech, INC. | $49.25 | 2022-2023 | |
| Mallinckrodt Enterprises LLC | $49.19 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $48.87 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $46.52 | 2023 | Fycompa |
| Almatica Pharma LLC | $43.81 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $35.87 | 2023-2024 | Dojolvi |
| Astrazeneca Pharmaceuticals Lp | $35.80 | 2023-2024 | |
| Ge Healthcare | $31.00 | 2020-2025 | |
| Tris Pharma INC | $25.78 | 2019-2024 | |
| Octapharma USA, INC. | $22.86 | 2024 | Panzyga |
| Life Molecular Imaging Ltd | $17.76 | 2024 | Neuraceq |
| Biomarin Pharmaceutical INC. | $15.85 | 2024 | Brineura |
| Vertical Pharmaceuticals, LLC | $14.71 | 2019 | |
| Vanda Pharmaceuticals INC. | $12.46 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,292.30 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mcallister listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.